Barclays reissued their top pick rating on shares of AstraZeneca (LON:AZN) in a report released on Friday morning, Marketbeat.com reports. Barclays currently has a GBX 6,800 ($88.85) price objective on the biopharmaceutical company’s stock.
A number of other research analysts also recently commented on AZN. Credit Suisse Group set a GBX 5,900 ($77.09) target price on shares of AstraZeneca and gave the company a buy rating in a research report on Friday, July 27th. Kepler Capital Markets set a GBX 5,630 ($73.57) target price on shares of AstraZeneca and gave the company a buy rating in a research report on Wednesday, August 1st. Liberum Capital reaffirmed a hold rating on shares of AstraZeneca in a research report on Thursday. Shore Capital reaffirmed a hold rating on shares of AstraZeneca in a research report on Tuesday, October 30th. Finally, UBS Group set a GBX 5,900 ($77.09) target price on shares of AstraZeneca and gave the company a neutral rating in a research report on Thursday. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. AstraZeneca has a consensus rating of Hold and a consensus target price of GBX 5,831.89 ($76.20).
Shares of AZN traded up GBX 79 ($1.03) during midday trading on Friday, reaching GBX 6,172 ($80.65). The stock had a trading volume of 2,861,442 shares, compared to its average volume of 2,310,000. AstraZeneca has a 1-year low of GBX 4,260 ($55.66) and a 1-year high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.